NCT05815680 is a Phase 1 clinical trial of metformin in Overweight Subjects, sponsored by Innovent Biologics (Suzhou) Co. Ltd..

Who is sponsoring NCT05815680?

NCT05815680 is sponsored by Innovent Biologics (Suzhou) Co. Ltd..

What drugs are being tested in NCT05815680?

Interventions in NCT05815680: metformin, digoxin, IBI362, warfarin, atorvastatin.

What condition does NCT05815680 study?

NCT05815680 studies Overweight Subjects, Obese Subjects.

Is NCT05815680 still recruiting?

NCT05815680 is currently completed. Last updated 14 November 2023.

Last reviewed 2023-11-14 · How we verify

NCT05815680

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects

Completed Phase 1 Last updated 14 November 2023

What this trial tests

Phase 1 trial testing metformin in Overweight Subjects in 48 participants. Completed in 30 October 2023.

Timeline

6 April 2023

Primary endpoint
18 August 2023

30 October 2023

Quick facts

Lead sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	48
Start date	6 April 2023
Primary completion	18 August 2023
Estimated completion	30 October 2023
Sites	1 location across China

Drugs / interventions tested

metformin (metformin) — full drug profile →
digoxin (digoxin) — full drug profile →
IBI362
warfarin (warfarin) — full drug profile →
atorvastatin (atorvastatin) — full drug profile →

Conditions studied

Overweight Subjects — all drugs for Overweight Subjects →
Obese Subjects — all drugs for Obese Subjects →

Sponsor

Innovent Biologics (Suzhou) Co. Ltd. — full company profile →

Who can join

Adults 18 to 45, male only, with Overweight Subjects or Obese Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is conducted in China. The aim of the trial is to investigate the influence of IBI362 on pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of warfarin, metformin, warfarin, atorvastatin, digoxin in overweight or obese subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of metformin

Trials testing the same drug.

NCT06463743 — Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS) · Phase 2 · recruiting
NCT06679413 — A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants · Phase 1 · completed
NCT05966792 — SGLT2 Inhibitors in Treating Patients With PCOS · NA · completed
NCT05767515 — The Effects of Acetyl-L-Carnitine and Myo/Chiro-Inositol in Patients With PCOS · NA · completed
NCT05468554 — Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer · Phase 3 · not yet recruiting

Other Innovent Biologics (Suzhou) Co. Ltd. trials

Trials by the same sponsor.

NCT07502534 — A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteers · Phase 1 · not yet recruiting
NCT07469800 — Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity · Phase 3 · not yet recruiting
NCT07473960 — IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia · Phase 3 · recruiting
NCT07483567 — IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastri · Phase 2 · not yet recruiting
NCT07483554 — IBI343 in Combination Therapy for Advanced Malignant Solid Tumors · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05815680 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Innovent Biologics (Suzhou) Co. Ltd.
Last refreshed: 14 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05815680.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing